Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
76 of 180 long COVID-associated genes also linked to ME
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Now a test that offers new precision in prostate cancer detection
The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
Subscribe To Our Newsletter & Stay Updated
